GlassScriptPhysician profile
Aimee Adamo
NPI 1447400296
$3,793.83
in general payments reported to CMS, 2019-2025
33 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,470 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,793.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.74 | 2024-2025 | |
| Amgen INC. | $385.85 | 2024-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $348.57 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $327.50 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $251.93 | 2024-2025 | Ingrezza |
| Amylyx Pharmaceuticals, INC. | $178.54 | 2024 | Relyvrio |
| Biogen, INC. | $174.15 | 2024-2025 | Leqembi, Vumerity, Tysabri |
| Eisai INC. | $168.53 | 2024-2025 | |
| Grifols USA, LLC | $167.51 | 2024-2025 | Gamunex-C |
| Acadia Pharmaceuticals INC | $146.42 | 2024-2025 | Nuplazid |
| Lilly USA, LLC | $142.85 | 2024-2025 | Amyvid, Kisunla |
| Ucb, INC. | $113.37 | 2025 | Fintepla, Briviact |
| Vertex Pharmaceuticals Incorporated | $84.73 | 2025 | |
| Sk Life Science, INC. | $78.00 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $70.39 | 2025 | Crexont |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $69.74 | 2024 | Nourianz |
| Genzyme Corporation | $66.04 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.05 | 2024-2025 | Hyqvia |
| Csl Behring | $60.24 | 2024-2025 | Hizentra |
| Lundbeck LLC | $47.27 | 2024-2025 | Vyepti, Rexulti |
| Astrazeneca Pharmaceuticals LP | $44.31 | 2025 | Wainua |
| Ge Healthcare | $41.94 | 2025 | |
| Neurelis, INC. | $34.56 | 2024 | Valtoco |
| Medtronic, INC. | $32.00 | 2024 | Percept PC Brainsense |
| Acorda Therapeutics, INC | $30.29 | 2024 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $29.66 | 2024 | Rexulti |
| Tanabe Pharma America, INC. | $28.83 | 2024 | |
| Axsome Therapeutics, INC. | $24.85 | 2025 | Symbravo |
| Scilex Pharmaceuticals INC. | $23.16 | 2025 | |
| Emd Serono, INC. | $23.10 | 2025 | |
| Pfizer INC. | $21.87 | 2024 | |
| Alnylam Pharmaceuticals INC. | $16.76 | 2025 | Amvuttra |
| Vanda Pharmaceuticals INC. | $16.08 | 2024 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Adamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.